Purchase this article with an account.
D. E. Welch, S. Adams, M. Peden, R. Ratnakaram, S. Kaushal; Reduction of Macular Edema at One Hour Following Intravitreal Bevacizumab as Demonstrated by Serial Octs. Invest. Ophthalmol. Vis. Sci. 2008;49(13):339. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Subjects with either CSME or exudative ARMD receiving IV bevacizumab participated. ETDRS visual acuity and OCT measurement of macular thickness were obtained at baseline then at 1, 3, 6, 24 and 48 hours as well as at 1 week and 1 month post injection.
Six subjects with eight eyes have been enrolled to date. All were female with an average age of 58 years. Five were diagnosed with CSME and one with exudative ARMD. Planned comparisons with dependent sample t-tests revealed significant reduction in macular edema as measured by OCT at 1, 3, and 6 hours compared to baseline (mean reductions 13.9, t (7) = 2.35, p < 0.05; 22.63, t(7) = 3.13, p < 0.05; and 17.63, t (7) = 2.5, p < 0.05 respectively). When compared to baseline, there were no significant change in macular edema at 24 or 48 hours nor 1 week or 1 month. Additionally, there were no significant differences in visual acuity across times.
This PDF is available to Subscribers Only